SECOND SIGHT MEDICAL PRODUCTS, INC. (NASDAQ:EYES) Files An 8-K Other Events
Item 9.01.Other Events.

On September 15, 2018, Second Sight Medical Products, Inc. (the “Company”) received a Notice of Award from the National Institutes of Health (“NIH”) for grant 1UH3NS103442-01. The Company has received a $1.6 million grant (with intent to fund $6.3 million over five years subject to annual review and approval) from the NIH to fund the “Early Feasibility Clinical Trial of a Visual Cortical Prosthesis”.

On September 18, 2018, the Company issued a press release entitled “Second Sight Receives $1.6 Million Grant from National Institutes of Health to Support Orion Clinical Development”. A copy of the press release is attached to this Current Report on Form 8-K as Exhibit 99.1 and is incorporated by reference herein.

Item 9.01.Financial Statements and Exhibits.

(d)Exhibits.

SIGNATURES

SECOND SIGHT MEDICAL PRODUCTS INC Exhibit
EX-99.1 2 ex_124109.htm EXHIBIT 99.1 ex_124109.htm Exhibit 99.1       FOR IMMEDIATE RELEASE   Second Sight Receives $1.6 Million Grant from National Institutes of Health to Support Orion Clinical Development   –Total Grant Amount Up to $6.3 Million Over Five Years–   Los Angeles,…
To view the full exhibit click here

About SECOND SIGHT MEDICAL PRODUCTS, INC. (NASDAQ:EYES)

Second Sight Medical Products, Inc. is engaged in developing, manufacturing and marketing prosthetic devices that restore vision to blind individuals. The Company’s product, the Argus II System, treats outer retinal degenerations, such as retinitis pigmentosa (RP). The Argus II System provides an artificial form of vision that differs from the vision of people with normal sight. It does not restore normal vision and it does not slow or reverse the progression of the disease. The Company’s Argus II System employs electrical stimulation to bypass degenerated photoreceptor cells and to stimulate remaining viable retinal cells thereby inducing visual perception in blind individuals. The Argus II System works by converting video images captured by a miniature camera housed in a patient’s glasses into a series of small electrical pulses that are transmitted wirelessly to an array of electrodes that are implanted on the surface of the retina.